MYCN overexpression predicts poor overall and event-free survivalin patients with ovarian cancer and neuroblastoma37 (Figure S7) and other malignancies.38−45 We investigate whether targeting VDR by 5 can inhibitMYCN expression and, in turn, control the MYCN-orchestrated neuroblastomagrowth. Here, MYCN is linked to ovarian carcinoma.